NICE Stock Recent News

NICE LATEST HEADLINES

NICE Stock News Image - businesswire.com

LONDON--(BUSINESS WIRE)--Route 101 a leading cloud systems integrator, announced today in collaboration with NiCE (Nasdaq: NICE), a major contract win with the Department for Work and Pensions (DWP) of the UK government. This contract will see Route 101 and NiCE collaborate to enable the transformation of citizen experiences with the delivery of a UK-sovereign Citizen Experience Platform (CXP), powered by NiCE's CXone Mpower and hosted in a secure, UK-based cloud environment. This initiative wi.

businesswire.com 2025 Jun 06
NICE Stock News Image - zacks.com

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

zacks.com 2025 Jun 05
NICE Stock News Image - businesswire.com

HOBOKEN, N.J.--(BUSINESS WIRE)-- #AI--NiCE (Nasdaq: NICE) today announced the winners of its 2025 International Partner Awards at the Partner Summit events held in Croatia and Thailand. These honorees are helping our customers drive innovation, meet ambitious timelines, and deliver success in the new era of customer service automation with CXone Mpower. Winners were recognized across several categories. Standout partner wins included: UK&I Partner of the Year – A 23-year partnership excelling in.

businesswire.com 2025 Jun 05
NICE Stock News Image - zacks.com

Investors interested in stocks from the Internet - Software sector have probably already heard of Nice (NICE) and VERRA MOBILITY CORP (VRRM). But which of these two stocks is more attractive to value investors?

zacks.com 2025 Jun 03
NICE Stock News Image - zacks.com

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

zacks.com 2025 Jun 03
NICE Stock News Image - zacks.com

Nice (NICE) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, NICE broke through the 200-day moving average, which suggests a long-term bullish trend.

zacks.com 2025 May 30
NICE Stock News Image - zacks.com

Nice (NICE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

zacks.com 2025 May 30
NICE Stock News Image - businesswire.com

HOBOKEN, N.J.--(BUSINESS WIRE)-- #AI--NICE Actimize, a NICE (NASDAQ: NICE) business, today announced its information-packed agenda for ENGAGE 2025, the industry's premier financial crime and compliance industry event. To be held on June 17-18 at New York's Sheraton Times Square Hotel, NICE Actimize's ENGAGE will bring together financial institutions thought leaders and subject matter experts to discuss the technology advancements and best practices in financial crime fighting. More than 200 companies.

businesswire.com 2025 May 29
NICE Stock News Image - businesswire.com

HOBOKEN, N.J.--(BUSINESS WIRE)-- #AI--NICE Actimize, a NICE (NASDAQ: NICE) business, today announced that its market-leading SURVEIL-X Holistic Conduct Surveillance solution is now integrated with Actimize Intelligence, powerful Generative AI capabilities designed to ensure accurate and timely detection of market abuse and conduct risks across every type of regulated employee communication, from emails and chats to traditional voice calls. Created to address the growing complexities of financial crim.

businesswire.com 2025 May 28
NICE Stock News Image - prnewswire.com

First non-immunosuppressive dual-action therapy recommended by NICE for eligible patients with IgA nephropathy, a leading cause of kidney failure 1-3 NICE's recommendation is based on clinically meaningful results from the phase-III PROTECT trial 4 ST. GALLEN, Switzerland , May 23, 2025 /PRNewswire/ -- CSL Vifor is pleased to announce that the National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending that sparsentan can be used in the NHS in England as an option to treat primary IgA nephropathy in adults with a urine protein excretion of 1.0 g/day or more, or a urine protein-to-creatinine ratio of 0.75 g/g or more.3 NICE has provided guidance to ensure that only patients responding to treatment continue.3 The decision follows authorisation from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) in April 2025.5 What this means in practice is that there is enough evidence to show that sparsentan provides benefits and value

prnewswire.com 2025 May 23
10 of 50